4.5 Article

The frequency of Duchenne muscular dystrophy/Becker muscular dystrophy and Pompe disease in children with isolated transaminase elevation: results from the observational VICTORIA study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping

E. Mercuri et al.

Summary: This study evaluated the safety, tolerability, and pharmacokinetics of Eteplirsen in boys aged 6-48 months. The results showed that Eteplirsen was well tolerated in boys of this age group, with no treatment-related discontinuations, deaths, or evidence of kidney toxicity. These data support the safety and tolerability of Eteplirsen in boys as young as 6 months old.

NEUROMUSCULAR DISORDERS (2023)

Review Clinical Neurology

Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview

David Stevens et al.

Summary: This review provides a summary of the clinical presentation and current diagnostic strategies for Pompe disease. It also discusses available treatment options and ongoing research. Recent findings include the inclusion of Pompe disease in newborn screening programs and the completion of clinical trials for new forms of enzyme replacement therapy. However, there are still unmet needs in terms of long-term effectiveness and tissue penetration of these treatments. Future developments include gene therapy and glycogen substrate reduction for Pompe disease and other glycogen storage disorders.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2022)

Article Nutrition & Dietetics

The Relationship between Obesity and Clinical Outcomes in Young People with Duchenne Muscular Dystrophy

Natassja Billich et al.

Summary: DMD patients, especially young people, have a high prevalence of obesity, which may negatively affect clinical outcomes, including an increased risk of fractures and OSA, as well as potential impacts on physical function milestones. Early weight management interventions are therefore crucial in this population.

NUTRIENTS (2022)

Article Genetics & Heredity

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures

P. Vanherpe et al.

ORPHANET JOURNAL OF RARE DISEASES (2020)

Review Genetics & Heredity

Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis

Salvatore Crisafulli et al.

ORPHANET JOURNAL OF RARE DISEASES (2020)

Review Clinical Neurology

Update in Duchenne and Becker muscular dystrophy

Megan A. Waldrop et al.

CURRENT OPINION IN NEUROLOGY (2019)

Review Medicine, General & Internal

Evaluation of abnormal liver function tests

Swastik Agrawal et al.

POSTGRADUATE MEDICAL JOURNAL (2016)

Article Gastroenterology & Hepatology

Dysferlin-Deficient Muscular Dystrophy Identified Through Laboratory Testing for Elevated Aminotransferases

Tyler Aasen et al.

ACG CASE REPORTS JOURNAL (2016)

Article Biotechnology & Applied Microbiology

Serum Enzyme Profiles Differentiate Five Types of Muscular Dystrophy

Yuling Zhu et al.

DISEASE MARKERS (2015)

Review Clinical Neurology

Pompe Disease Literature Review and Case Series

Majed Dasouki et al.

NEUROLOGIC CLINICS (2014)

Review Pediatrics

Aminotransferases and muscular diseases: A disregarded lesson. Case reports and review of the literature

Claudio Veropalumbo et al.

JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2012)

Article Primary Health Care

Consider Muscle Disease in Children with Elevated Transaminase

Melissa A. Wright et al.

JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE (2012)

Article Gastroenterology & Hepatology

Duchenne and Becker Muscular Dystrophy Presenting as Nonalcoholic Fatty Liver Disease

C. Veropalumbo et al.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2011)